贝伐单抗
医学
卵巢癌
妇科癌症
肿瘤科
卵巢癌
化疗
内科学
癌
癌症
作者
Tadahiro Shoji,Eriko Takatori,Takayuki Nagasawa,Masahiro Kagabu,Tsukasa Baba,Tatsuhiko Shigeto,Yukiko Matsumura,Dai Shimizu,Yukihiro Terada,Manabu Seino,Tsuyoshi Ohta,Satoru Nagase,Shogo Shigeta,Hideki Tokunaga,Muneaki Shimada,Michiko Kaiho-Sakuma,Shigenori Furukawa,Shu Soeda,Takafumi Watanabe,Fumiaki Takahashi,Yoshihito Yokoyama
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2024-11-12
卷期号:16 (22): 3801-3801
标识
DOI:10.3390/cancers16223801
摘要
: The usefulness of bevacizumab (BEV) as first-line chemotherapy for advanced ovarian clear cell carcinoma (CCC) was retrospectively evaluated at Tohoku Gynecologic Cancer Unit institutions.
科研通智能强力驱动
Strongly Powered by AbleSci AI